Keyphrases
Promoter Methylation
100%
Blood Biomarkers
100%
Pancreatic Ductal Adenocarcinoma
100%
SFRP1
100%
Poor Prognosis
20%
Free-free
10%
Kaplan-Meier Curve
10%
Adjusted Analysis
10%
Treatment Process
10%
Promoter Region
10%
Linear Regression Analysis
10%
Disease Progression
10%
Progression-free Survival
10%
Worse Prognosis
10%
Patient Survival
10%
Disease-free
10%
Median Overall Survival
10%
Log-rank Test
10%
Pancreatic Adenocarcinoma
10%
Gemcitabine
10%
Bisulfite Treatment
10%
Adjuvant Chemotherapy
10%
Low Stage
10%
Restricted Mean Survival Time
10%
Epigenetically
10%
Quantitative Methylation-specific PCR (Q-MSP)
10%
SFRP1 Gene
10%
Generalized Linear Regression
10%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Pancreas Adenocarcinoma
100%
Chemotherapy
50%
Bisulfite
50%
Disease
50%
Overall Survival
50%
Progression Free Survival
50%
Gemcitabine
50%
Survival Time
50%
Medicine and Dentistry
Promoter Region
100%
Biological Marker
100%
Pancreas Adenocarcinoma
100%
Pancreatic Ductal Adenocarcinoma
62%
Diseases
12%
Kaplan Meier Method
12%
Linear Regression Analysis
12%
Progression Free Survival
12%
Overall Survival
12%
Log Rank Test
12%
Survival Time
12%
Gemcitabine
12%
Adjuvant Chemotherapy
12%
Clinician
12%
Polymerase Chain Reaction
12%
Methylation
12%
Bisulfite
12%
Biochemistry, Genetics and Molecular Biology
Promoter Region
100%
Methylation
12%
Polymerase Chain Reaction
12%
Gemcitabine
12%
Progression Free Survival
12%
Overall Survival
12%
Survival Time
12%
Bisulfite
12%
Immunology and Microbiology
Promoter Region
100%
Polymerase Chain Reaction
12%
Overall Survival
12%
Progression Free Survival
12%
Methylation
12%
Survival Time
12%